This page is updated frequently with new Factor-related patent applications.
|| List of recent Factor-related patents
|System and managing binge eating disorders|
Systems, methods, devices, and applications for managing a binge eating disorder (bed). A smartphone and server application may be provided for monitoring and treating bed.
|Cardiovascular disease risk assessment|
The invention provides improved methods for analyzing cardiovascular disease risk. According to the invention, an algorithm that considers ldl and hdl subfractions, along with lp(a) provides significant improvement in predicting cvd versus standard assays that include standard risk factors.
Boston Heart Diagnostic Corporation
|Methods and compositions relating to neurodegenerative diseases|
The present invention provides a method for diagnosing or assessing a neurodegenerative disease in a test subject, comprising: (i) providing a protein-containing sample that has been obtained from the test subject; (ii) determining the concentration, amount or degree of expression of at least one specific protein isoform and/or glycoform derived from a protein biomarker selected from the group consisting of: clusterin precursor; apolipoprotein a-iv precursor; apolipoprotein c-iii precursor; transthyretin; galectin 7; complement c4 precursor; alpha-2-macroglobulin precursor; ig alpha-1 chain c; histone 2b; ig lambda chain c region; fibrinogen gamma chain precursor; complement factor h; inter-alpha-trypsin heavy chain h4 precursor; complement c3 precursor; gamma or beta actin; haptoglobin precursor; and the serum albumin precursor, or a fragment thereof; (iii) comparing said concentration, amount or degree determined in (ii) with a reference from a control subject with a specific neurodegenerative disease, dementia or stage of disease, or from a control subject that does not have a neurogenerative disease or dementia; and (iv) based on the level of the at least one specific protein isoform and/or glycoform of the protein biomarker in the test subject relative to the reference, making a diagnosis or assessment as to the presence of and/or stage of neurodegenerative disease or dementia of the test subject. Also provided are related products and systems for use in such a method..
|Biomarkers for the diagnosis and the response to treatment of pancreatic cancer|
The invention related to biomarkers, a method and a kit for early diagnosis of pancreatic cancer, in particular of pancreatic ductal adenocarcinoma (pdac); and to biomarkers, a method and a kit or device for predicting or prognosticating an individual's response to combination treatment with a nucleoside analogue (preferably gemcitabine) and with a growth factor receptor (preferably erlotinib) in patients with pancreatic ductal adenocarcinoma.. .
Universidad De JaÉn
|Submersible multi-parameter sonde having a high sensor form factor sensor|
Provided are multi-parameter sonde systems having a unique form-factor, wherein the plurality of sensors are arranged in a tight-fit configuration. This provides a single distal sensing surface and minimal separation distance between adjacent sensors.
|Method for inactivating target transcription factor using artificial small interfering peptide and use thereof|
The present invention relates to a method for targeted inactivation of transcription factor using an artificial small interfering peptide and a use thereof. According to the present invention, an artificial small interfering peptide (a-sipep) as a truncated from of the transcription factor for regulating transcription by dimerization was produced.
Snu R&db Foundation
|Novel genes involved in biosynthesis|
The invention provides a novel myb class transcription factor gene (nucleic acid sequences, protein sequences, and variants and fragments thereof) designated myb14 by the applicants, that is useful for manipulating the production of flavonoids, specifically condensed tannins, in plants. The invention provides the isolated nucleic acid molecules encoding proteins with at least 70% identity to any one of myb14 polypeptide sequences of seq id no: 14 and 46 to 54.
Grasslanz Technology Limited
The present disclosure relates to a method of preparing exonuclease resistant molecules of block-decoys, use of the molecules in methods of modulating expression of recombinant proteins, particularly in vitro, for example by down regulation or inhibition of one or more transcription factors, and novel molecules of block-decoys, especially those obtained or obtainable from the methods herein. The disclosure also relates to use of said block decoys in vitro and in therapy.
Ucb Biopharma Sprl
|Crystal structure of blood coagulation factor xiiia|
The present invention relates to crystal forms of blood coagulation factor xiiia, crystal structure information obtained from them, methods of preparing such crystal forms, their use for the identification and/or design of inhibitors of blood coagulation factor xiiia activity and methods for identifying, optimizing and designing compounds which should have the ability to interact with or inhibit blood coagulation factor xiiia.. .
|New processes for the production of chemically-modified heparins|
The present invention relates to a process for the production of heparin derivatives having an average molecular weight of from about 4.6 to about 6.9 kda and an anti-factor xa activity of less than about 10 iu/mg, comprising the steps of oxidation of unfractionated heparin, depolymerisation and reduction of resulting terminal groups.. .
Antibody specifically binding to insulin-like growth factor-1
Isolated antibodies that specifically bind to an epitope comprised in the stretch of amino acids ranging from amino acid 76 to amino acid 84 of human insulin-like growth factor-1 precursor (seq id no:1). Use of the novel antibodies for the sensitive and specific detection of insulin-like growth factor-1, in some embodiments while in the presence of high excess concentration of insulin-like growth factor-2, for example in a bodily fluid sample..
Roche Diagnostics Operations, Inc.
Novel compounds and uses thereof
The present invention provides novel compounds of any one of formulae (i)-(iv), and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of any one of formulae (i)-(iv) and pharmaceutical compositions thereof that are mucus penetrating.
Kala Pharmaceuticals, Inc.
Three-dimensional scaffold functionalized with micro-tissues for tissue regeneration
The present invention concerns a biomaterial devoid of a growth factor, comprising: —a three-dimensional scaffold made of a biocompatible polymer; and—living cells, wherein said living cells are in form of microtissues and the nanofibrous three-dimensional scaffold is a nanofibrous scaffold. It further concerns a method for manufacturing such a biomaterial.
Universite De Strasbourg
Polymers for delivery of factor viii and/or factor ix
In some aspects, a composition comprising a ph-sensitive crosslinked copolymer of methacrylic acid and poly(ethylene glycol) monomethyl ether methacrylate and a therapeutic protein is provided. In some embodiments, the therapeutic protein is a high molecular weight protein such as factor viii or factor ix.
Board Of Regents, The University Of Texas System
System having a miniature portable electronic device for command and control of a plurality of wireless devices
Disclosed system comprising a miniature portable electronic device for interacting with a plurality of electronic devices including at least one smart device, at least one wireless electronic device and at least one remote web server connected to the miniature portable electronic device over a wireless communication network. The system allows a user of the miniature portable electronic device to have partial and/or full control of a variety of electronic devices connected to the miniature portable electronic device over the wireless network.
Multi-tonal box drum kit
The present invention generally relates to cajón drums. Specifically, this invention relates to a multi-tonal box drum kit that provides a form factor that is easy and convenient to use while producing the tones and sounds of a full drum kit or some subset thereof..
Preventing sharing of sensitive information through code repositories
Methods, systems, and computer program products for preventing sharing of sensitive information through code repositories are provided herein. A method includes detecting one or more items of sensitive information in a check-in associated with a given user in a shared version management system; automatically refactoring the one or more items of sensitive information in the check-in by externalizing the one or more items of sensitive information as an encrypted file; and upon acceptance by the user of one or more changes to the check-in, automatically (i) decrypting the encrypted file using one or more code repository credentials associated with the given user, and (ii) incorporating the one or more items of sensitive information into the check-in..
International Business Machines Corporation
Enhanced view transitions
Systems, methods, and software are disclosed herein that enhance the content viewing experience on computing devices having small form factors relative to larger devices. In an implementation, an application detects when a view transition is invoked.
Microsoft Technology Licensing, Llc
Fiber optic cable with electrical connectors at both ends, wall plates and control boxes
A connecting device for a fiber optic cable includes a first part having first and second electrical connectors located on its housing, and a second part having a third electrical connector located on its housing. The second and third electrical connectors are adapted to be mechanically and electrically connect with each other or disconnected from each other.
Celerity Technologies Inc.
Nucleic acid sequences encoding transcription factors regulating alkaloid biosynthesis and their use in modifying plant metabolism
Plant metabolism and alkaloid levels can be regulated by transcription factors that regulate the nicotinic alkaloid biosynthetic pathway. In one embodiment, the disclosure provides a transcription factor that negatively regulates alkaloid biosynthesis, such as nicotine biosynthesis..
22nd Century Limited, Llc
Method of controlling a polypeptide modification reaction
The invention relates to a method of controlling a polypeptide modification reaction, in particular but not exclusively, a method of controlling the activation of human factor vii (fvii) to produce human factor vii(a) (fvii(a)). The invention also relates to polypeptides obtainable by the polypeptide modification reaction and to pharmaceutical compositions comprising said polypeptides..
Novo Nordisk Healthcare Ag
Cell populations, methods of transdifferentiation and methods of use thereof
The present invention provides methods for the sequential and temporally-regulated administration of pancreatic transcription factors to induce non-pancreatic cells to transdifferentiate and mature along the pancreatic β-cell lineage. The present invention also provides methods for identifying, isolating and enriching transdifferentiation predisposed cells and methods for treating a degenerative pancreatic disorder such as diabetes..
Tel Hashomer-medical Research, Infrastructure And Services Ltd.
Reprogramming mesenchymal stromal cells into hematopoietic cells
Method for reprogramming of stromal cells into hematopoietic cells are provided. Also provided are mesenchymal stromal cells that can be reprogrammed into hematopoietic cells.
Wake Forest University Health Sciences
Anti-factor viii antibodies or uses thereof
The present invention provides anti-fviii antibodies and antigen-binding molecules thereof which specifically bind fviii epitopes. The antibodies and antigen-binding molecules can be used to purify fviii.
Biogen Ma Inc.
Quinolone derivatives as fibroblast growth factor inhibitors
Compounds that are fibroblast growth factor inhibitors (fgfr) and are therefore useful for the treatment of diseases treatable by inhibition of fgfr are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds..
Principia Biopharma, Inc.
Risk assessment framework
Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for receiving data related to a first flight risk factor and a second flight risk factor where the first and second risk factors include one of: a proficiency risk factor, an equipment risk factor, an environmental risk factor, or a performance risk factor. Applying a first weighting to the first flight risk factor to generate a first weighted flight risk factor, and applying a second weighting to the second flight risk factor to generate a second weighted flight risk factor.
Federal Express Corporation
Enhanced ribbon loading and unloading features
A device for processing media may include a system and method for loading and unloading consumable supplies of a printer, and more particularly, a system and method for providing a compact form factor printer which provides convenient access to the replaceable components of the printer. A printer may include a base and a lid hingedly attached to the base, moveable between a closed position in which the lid is secured to the base, and an open position.
Factor viia-polysialic acid conjugates having prolonged in vivo half-life
The present invention relates to a proteinaceous construct comprising plasmatic or recombinant factor viia (fviia) or biologically active derivatives thereof, which are bound to a carbohydrate moiety comprising 1-4 sialic acid units, wherein the in vivo half-life of the proteinaceous construct is substantially prolonged in the blood of a mammal, as compared to the in vivo half-life of a fviia molecule not bound to a carbohydrate moiety. The invention also provides a method for controlling bleeding in a mammal having a bleeding disorder due to functional defects or deficiencies of fviia, fviii, or fix.
The present disclosure relates to a method for treatment or prevention of diseases have an increased level of insulin-like growth factor i (igf-i). The method comprises administration of a somatostatin analogs having agonistic activity in combination with an oligonucleotide targeted to growth hormone receptor (ghr) to a subject in need..
Antisense Therapeutics Ltd
Therapeutic dosing of a neuregulin or a fragment thereof for treatment or prophylaxis of heart failure
The invention relates to treatment and prevention of heart failure in a mammal. The invention provides a dosing regimen whereby the therapeutic benefits conferred by administration of peptide comprising an epidermal growth factor-like domain, e.g., a neuregulin such as glial growth factor 2 (ggf2) or a functional fragment thereof, are maintained and/or enhanced, while concomitantly minimizing any potential side effects..
Acorda Therapeutics, Inc.
Needle guide devices for mounting on imaging transducers or adaptors on imaging transducer, imaging transducers for mounting needle guide devices and adaptors for imaging transducers for mounting needle guide devices thereon
A needle guide device for releasable mounting on an imaging transducer or on an adaptor bracket on an imaging transducer is disclosed. The needle guide device includes a universal lockable mounting member which is configured for slidable releasable engagement with a coupling member on a specially constructed imaging transducer or on a conventional imaging transducer onto which a specially constructed adaptor is mounted.
Civco Medical Instruments Co., Inc.
Hybrid cavity and lumped filter architecture
A resonator includes an inductive element and a conductive cavity surrounding the inductive element. In particular, the conductive cavity surrounds the inductive element such that a capacitance is distributed between the inductive element and the conductive cavity.
Rf Micro Devices, Inc.
Method for manufacturing solar cell having selective emitter and solar cell manufactured thereby
The present invention relates to a method for manufacturing a solar cell comprising a selective emitter, the method comprising the steps of: forming an electrode pattern and an alignment mark by performing a first impurity doping locally on one surface of a substrate; and performing a second impurity doping on the entire surface of the first doped substrate, wherein, as a result of the first and second doping, the alignment mark is formed on a first emitter or a second emitter, and the electrode pattern is formed on the second emitter. When manufacturing the selective emitter, the alignment mark is formed by doping processes.
Samsung Sdi Co., Ltd.
Multifactorial leveraged indexed investment product
A computer-implemented method is presented for structuring and maintaining a leveraged indexed investment product, also known as leveraged exchange-traded fund, leveraged etf, and letf. The method comprises determining a leverage adjustment protocol, monitoring the leverage of the product, and calculating a target leverage adjustment in accordance with the protocol.
System and securing an architectural environment against crime and minimizing criminal elements
A computer-implemented method is provided for analysing and designing a physical environment for discouraging criminal activity within the physical environment. The physical environment is assessed and risk factors are identified that make the physical environment vulnerable to criminal activity.
Safe Design Technologies Inc.
System for management of health resources
A computer implemented method of identifying individuals having a predicted susceptibility and/or level of risk to repeated visits to a medical facility within a defined time period following an initial visit is provided. The method includes accessing an evaluation data store of historical patient data representing clinical history of each patient in the patient population.
Healthcare Business Intelligence Solutions Inc.
Identifying improvements to memory usage of software programs
The disclosed embodiments provide a system that facilitates the execution of a software program. During operation, the system determines a structure of a software program and an execution context for the software program from a set of possible execution contexts for the software program, wherein the software program includes one or more object instances.
Oracle International Corporation
Detection of protein to protein interactions
The present invention relates to methods and kits for detecting the interaction between a first membrane protein and a second protein in mammalian cells as well as to identify molecules that can disrupt protein to protein interactions. The invention relies on the functional reconstitution of an active human ubiquitin by two inactive fragments upon the interaction of two proteins attached through a linker to the inactive fragments.
The Governing Council Of The University Of Toronto
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of prostatic acid phosphatase, lactotransferrin, soluble erythropoietin receptor, von willebrand factor, soluble endothelial protein c receptor, and beta-2-glycoprotein 1 as diagnostic and prognostic biomarkers in renal injuries..
Astute Medical, Inc.
Plant with reduced protein productivity in seeds and producing same
According to the present invention, a gene having a novel function that can cause an increase or decrease in seed protein content is searched for. A chimeric protein obtained by fusing a transcription factor consisting of a protein comprising an amino acid sequence shown in any of the even-numbered seq id nos: 1 to 76 and a functional peptide capable of converting an arbitrary transcription factor into a transcriptional repressor or a transcription factor consisting of a protein comprising an amino acid sequence shown in any of the even-numbered seq id nos: 77 to 84 is expressed in a plant..
Toyota Jidosha Kabushiki Kaisha
Factor ix polypeptide mutant, its uses and its production
Disclosed are a modified fix (factor ix) polypeptide comprising a leucine, cysteine, aspartic acid, glutamic acid, histidine, lysine, asparagine, glutamine or tyrosine in position 338; pharmaceutical preparations containing said modified fix polypeptide; a nucleotide sequence coding for the modified fix polypeptide; and a method for producing the modified fix polypeptide.. .
Factor ix variants and methods of use therefor
Modified factor ix (fix) polypeptides, nucleic acid encoding the same, and methods of generating modified factor ix polypeptides are provided. Also provided are pharmaceutical compositions that contain the modified factor ix polypeptides, methods of treatment using modified factor ix polypeptides, and assay for factor ix activity..
Wisconsin Alumni Research Foundation
Serum-free medium containing pdgf for ds cells
The problem to be solved by the present invention is to provide a serum-free medium suitable for culturing of ds cells. The present invention relates to a serum-free medium for culturing of ds cells containing platelet-derived growth factor (pdgf), or to a method for culturing of dermal sheath (ds) cells, using serum-free medium comprising pdgf..
Shiseido Company, Ltd.
Method and pharmaceutical composition for continuously maintaining growth of a motor neuron progenitor cell
This present invention provides a method for continuously maintaining growth of a motor neuron progenitor cell and a pharmaceutical composition. Wherein, the method for continuously maintaining growth of a motor neuron progenitor cell is to culture the motor neuron progenitor cell in an environment which is constructed by the olfactory ensheathing cells to make the motor neuron progenitor cell sustain the ability to self-replicate and to be induced for differentiating into mature neuron, and therefore to elaborate the effect to protect the motor neuron.
National Chung Hsing University
Anti-pdgfr-beta antibodies and uses thereof
The present invention provides antibodies that bind to platelet derived growth factor receptor beta (pdgfr-beta) and methods of using the same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human pdgfr-beta with high affinity.
Regeneron Pharmaceuticals, Inc.
Anti-tnf- / anti-il-23 bispecific antibodies
Bispecific antibodies are provided that bind tumor necrosis factor alpha (tnfα) and the p19 subunit of interleukin-23 (il-23p19) and are characterized as having high affinity and strong simultaneous neutralizing properties to both tnfα and il-23. The bispecific antibodies of the invention are useful for treating various autoimmune diseases including inflammatory bowel disease, such as crohn's disease and ulcerative colitis, axial spondyloarthropathy, rheumatoid arthritis and psoriatic arthritis..
Eli Lilly And Company
Anti-vegf antibody, and pharmaceutical composition for preventing, diagnosing or treating cancer or angiogenesis-related diseases, containing same
A novel anti-vascular endothelial growth factor (vegf) antibody having a strong binding affinity for vegf and capable of inhibiting in vivo tumor growth and a composition for the treatment of cancer, containing the same. The antibody shows a remarkable binding property to human and mouse vegf, suppresses the proliferation and permeability of a human umbilical vein endothelial cell (huvec) and inhibits tumor growth, and thus can be useful as an antibody for the treatment of cancer..
Dong-a St Co., Ltd
Methods for treating diabetes
Methods for treating diabetes by administering an inhibitor of gdf-8, or a related member of transforming growth factor-beta (tgf-β) superfamily of structurally-related growth factors (e.g., gdf-11) are disclosed. Also disclosed are methods for upregulating expression of hexose transporters, such as glut4 and glut 1, in a subject by administering an inhibitor of gdf-8.
Cartilage-binding fusion proteins
Provided herein are fusion proteins comprising a first domain that specifically binds to the extracellular domain of a growth factor receptor, and a second domain that specifically binds to a cartilage matrix component, and pharmaceutical composition comprising these fusion proteins. Methods of treating musculoskeletal diseases using the fusion proteins and pharmaceutical composition disclosed herein are also provided..
Merrimack Pharmaceuticals, Inc.
Coagulation factor vii polypeptides
The present invention relates to modified coagulation factor vii polypeptides exhibiting increased resistance to antithrombin inactivation and enhanced proteolytic activity. The present invention also relates to polynucleotide constructs encoding such polypeptides, vectors and host cells comprising and expressing such polynucleotides, pharmaceutical compositions, uses and methods of treatment..
Novo Nordisk Healthcare Ag
Factor viii conjugates
The present invention relates to fviii conjugated to heparosan (hep) polymers, methods for the manufacture thereof and uses of such conjugates. The resultant conjugates may be used in the treatment or prevention of bleeding disorders such as haemophilia..
Novo Nordisk A/s
Therapeutic agents comprising elastin-like peptides
The present invention provides therapeutic agents and compositions comprising elastin-like peptides (elps) and therapeutic proteins. In some embodiments, the therapeutic protein is a glp-1 receptor agonist, insulin, or factor vii/viia, including functional analogs.
Systemic and local ex vivo gene therapy of the skeleton
Methods are disclosed herein for increasing bone mass and strength or bone fracture healing in a subject. The methods include administering to the subject a therapeutically effective amount of multipotent stem cells, wherein each multipotent stem cell is transformed with a recombinant nucleic acid molecule comprising a heterologous promoter operably linked to a nucleic acid encoding platelet derived growth factor (pdgf) b, and wherein the multipotent stem cells express a sufficient amount of pdgfb to increase bone mass and strength or bone fracture healing.
Loma Linda University
Stable neural stem cells comprising an exogenous polynucleotide coding for a growth factor and methods of use thereof
The present disclosure provides a human neural stem cell comprising an exogenous polynucleotide coding for a growth factor such as igf-1. Also disclosed are methods of using the human neural stem cells for the treatment of neurodegenerative diseases or disorders including, for example, als..
Pharmaceutical compositions comprising 8-substituted dibenzylbutyrolactone lignans
Therapeutic compositions comprising at least one 8-substituted-dibenzylbutyrolactone lignan, preferably a lignan is selected from the group of nortrachelogenin, diasteromeric forms of nortrachelogenin, isomeric forms of nortrachelogenin and combinations thereof as well as 8-methylmatairesinol and 8-methyldimethylmatairesinol, for use in a method of treating cancer or a similar condition wherein the growth factor signaling pathway of a mammal is deregulated. The invention also provides therapeutic pharmaceutical combinations comprising a hydroxy-dibenzylbutyrolactone lignan and at least one trail receptor agonist.
Extract of cynara ssp. and uses thereof
The present invention relates to an extract of cynara spp. And also to compositions and kits that comprise said extract for the prevention and/or the treatment of a pathological condition characterised by a constitutive activation of the stat3 transcription factor..
Aboca S.p.a. Societa' Agricola
Transplantation of cells into the nasal cavity and the subarachnoid cranial space
A method of transplanting cells into a subject is disclosed. The method comprises transplanting the cells into the paranasal sinus of the subject or the subarachnoid cavity situated between the frontal bone of skull and the olfactory bulb of the subject.
Ramot At Tel-aviv University Ltd.
Functional cosmetic composition characterized by containing growth factors and amino acids
The present invention relates to a functional cosmetic composition containing growth factors and amino acids, and more particularly to a functional cosmetic composition excellent in skin wrinkle improvement, skin resilience improvement, skin moisturization, skin reproduction and skin ageing prevention by containing, as growth factors, epidermal growth factors, fibroblast growth factors and vascular endothelial growth factors, and, as amino acids, proline, glycine and serine. The functional cosmetic composition containing 3 kinds of growth factors and collagen synthesis amino acid precursors and functional cosmetic containing the same have excellent effects on skin wrinkle improvement, skin resilience improvement, skin moisturization, skin reproduction and skin ageing prevention..
Human Biotech Co. Ltd.
Universal smart mobile electronic gear hub and specialty earphone case
A universal smart mobile electronic gear hub and specialty earphone case device for providing a user with functional tools, sensors, input/output interfaces, and electronic features in an easy to use, handheld, 360 degree form factor. The universality of the present invention in a novel form factor facilitates a new level of user interface, connectivity, monitoring, and systems for a plurality of technology devices.
Enlarged substrate for magnetic recording medium
An enlarged substrate for a magnetic recording medium used in a data storage device such as a hard disc drive (hdd). In some embodiments, a data storage device has a housing member for a 3½ inch form factor storage device or a 2½ inch form factor storage device.
Seagate Technology Llc
Breast imaging reporting and data system (bi-rads) tissue composition
Breast density is a significant breast cancer risk factor measured from mammograms. Disclosed is a methodology for converting continuous measurements of breast density and calibrated mammograms into a four-state ordinal variable approximating the bi-rads ratings.
H. Lee Moffitt Cancer Center And Research Institute, Inc.
Shared risk group management system, shared risk group management method, and shared risk group management program
Provided are a service influence degree calculation unit 11 that calculates a service influence degree that is a degree of an influence imposed on each service by a risk factor which is likely to influence execution of the service, the service influence degree calculated for each of the risk factor, a risk factor distance calculation unit 12 that calculates a distance between risk factors for indicating a similarity between risk factors based on the service influence degree for each of the risk factors, a shared risk group determination unit 13 that determines a group of risk factors which has the distance between risk factors meeting a first condition, as a shared risk group, and a shared risk group removal determination unit 14 that determines a shared risk group meeting a second condition from the shared risk groups, as a shared risk group to be removed.. .
Multiprocessor computing apparatus with wireless interconnect and non-volatile random access memory
A fan less multiprocessor computing apparatus (mca) is housed in a metallic enclosure (me) that acts as a heat sink and provides extended surface area for heat dissipation. The me also acts as an electro-magnetic-shield that provides immunity from electro-magnetic-interference (emi) from external stray magnetic fields to wireless communications among components of mca.